ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · Real-Time Price · USD
17.57
+0.05 (0.29%)
Jan 17, 2025, 4:00 PM EST - Market closed
ACADIA Pharmaceuticals Revenue
ACADIA Pharmaceuticals had revenue of $250.40M in the quarter ending September 30, 2024, with 18.28% growth. This brings the company's revenue in the last twelve months to $929.24M, up 47.06% year-over-year. In the year 2023, ACADIA Pharmaceuticals had annual revenue of $726.44M with 40.45% growth.
Revenue (ttm)
$929.24M
Revenue Growth
+47.06%
P/S Ratio
3.13
Revenue / Employee
$1,553,906
Employees
598
Market Cap
2.92B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 726.44M | 209.20M | 40.45% |
Dec 31, 2022 | 517.24M | 33.09M | 6.83% |
Dec 31, 2021 | 484.15M | 42.39M | 9.60% |
Dec 31, 2020 | 441.76M | 102.68M | 30.28% |
Dec 31, 2019 | 339.08M | 115.27M | 51.50% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
ACAD News
- 3 days ago - Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 days ago - Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 6 days ago - Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome - Business Wire
- 4 weeks ago - Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025 - Business Wire
- 5 weeks ago - Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million - Business Wire
- 6 weeks ago - Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer - Business Wire
- 7 weeks ago - Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET - Seeking Alpha
- 7 weeks ago - Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711 - Business Wire